File No. CT/63/21-DCG(I)

GOVERNMENT OF INDIA
CENTRAL DRUGS STANDARD CONTROL ORGANISATION (Headquarter)
(Directorate General of Health Services)
Ministry of Health & Family Welfare
FDA Bhavan
ITO, Kotla Road
New Delhi - 110002 (Delhi)
Phone No.: 91-11-23216367
Fax No.: 91-11-23236973
E-Mail : dci@nic.in

सत्यमेव जयते

File No. CT/21/000063

To,

M/s. Novo Nordisk India Pvt Ltd.,
Plot No.32, 47-50, EPIP Area, Whitefield,
Bangalore, Karnataka (India) – 560066.

Sir,

With reference to your application No. GCT/CT04/FF/2021/26224 (GCT/63/21) dated 05-06-2021, please find enclosed herewith the permission in Form CT-06 for conduct of clinical trial titled, "**ZEUS - Effects of ziltivekimab versus placebo on cardiovascular outcomes in participants with established atherosclerotic cardiovascular disease, chronic kidney disease and systemic inflammation, Protocol Number: EX6018-4758, Protocol Version 1.0 dated 16/April/2021** under the provisions of New Drugs and Clinical Trial Rules, 2019

The permission granted by the Central Licensing Authority to conduct clinical trial shall be subject to following conditions, namely:-

(i) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licencing Authority under rule 8;

(ii) where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:

Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:

Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;

(iii) in case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;

(iv) the Central Licencing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;

(v) clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial;

(vi) clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules;

(vii) status of enrolment of the trial subjects shall be submitted to the Central Licencing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;

(viii) six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licencing Authority electronically in the SUGAM portal;

(ix) in case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licencing Authority within thirty working days of such termination;

(x) any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licencing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI;

(xi) in case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of the receipt of order issued by Central Licencing Authority in accordance with the provisions of the said Chapter;

(xii) in case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licencing Authority within thirty working days of receipt of the order issued by the Central Licencing Authority in accordance with the provisions of the said Chapter;

(xiii) the premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licencing Authority who may be accompanied by officers of the State Licencing Authority or outside experts as authorised by the Central Licencing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial;

(xiv) where the new drug or investigational new drug is found to be useful in clinical development, the sponsor shall submit an application to the Central Licencing Authority for permission to import or manufacture for sale or for distribution of new drug in India, in accordance with Chapter X of these rules, unless otherwise justified;

(xv) the laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority;

(xvi) the Central Licencing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial;

(xvii) the sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.

(xviii) The permission to initiate clinical trial granted under rule 22 in form CT-06 or automatic approval under rule 23 in Form CT 4A shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Yours faithfully,

VENUGOPAL GIRDHARILAL SOMANI

Digitally signed by VENUGOPAL GIRDHARILAL SOMANI
DN: c=IN, o=MINISTRY OF HOME AFFAIRS, ou=CDSCO DGHS, postalCode=431401, st=Maharashtra, 2.5.4.20=173d03345df62d489632379a1471bfdae9f0b2bea56c83bfbbe2154e399b1af7, cn=VENUGOPAL GIRDHARILAL SOMANI
Date: 2021.09.03 14:37:20 +05'30'

(Dr. V. G. Somani)
Drugs Controller General (India)
Central Licencing Authority
Stamp

File No. CT/63/21-DCG(I)

FORM CT-06
(See rules 22,25,26,29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

1. The Central Licensing Authority hereby permits **M/s. Novo Nordisk India Pvt. Ltd., Plot No. 32, 47 - 50, EPIP Area, Whitefield Bangalore (India) - 560066** to conduct clinical trial of the new drug or investigational new drug as per **Protocol Number: EX6018-4758, Protocol Version 1.0 dated 16/April/2021** in the below mentioned clinical trial sites [As per Annexure].-

2. Details of new drug or investigational new drug and clinical trial site [As per Annexure].

3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.

Place: New Delhi
Date _____

VENUGOPAL GIRDHARILAL SOMANI

Digitally signed by VENUGOPAL GIRDHARILAL SOMANI
DN: c=IN, o=MINISTRY OF HOME AFFAIRS, ou=CDSCO DGHS, postalCode=431401, st=Maharashtra, 2.5.4.20=173d03345df62d489632379a1471bfdae9f0b2bea56c83bfbbe2154e399b1af7, cn=VENUGOPAL GIRDHARILAL SOMANI
Date: 2021.09.03 14:37:29 +05'30'

(Dr. V. G. Somani)
Drugs Controller General (India)
Central Licencing Authority
Stamp

Note: The permission to initiate clinical trial granted under rule 22 in form CT-06 shall remain valid for a period of **two years** from the date of its issue, unless extended by the Central Licencing Authority.

Annexure:

Details of new drug or investigational new drug:

Names of the new drug or investigational new drug	Ziltivekimab15 mg/ml
Therapeutic class:	Anti-inflammatory
Dosage form:	Solution for injection
Composition:	Water for injection = 1.0000 To 1 ml U.S.P., J.P., Ph. Eur Inactive Sodium hydroxide = 1.0000 q.s. U.S.P., J.P., Ph. Eur Inactive Hydrogen chloride = 1.0000 q.s. U.S.P. ,J.P., Ph. Eur Inactive Polysorbate 80 = 0.7000 milligram(mg) U.S.P., J.P. ,Ph. Eur Inactive L-Histidine mono hydrochloride monohydrate = 2.1000 milligram(mg) U.S.P.,J.P. Inactive L-Histidine = 1.5500 milligram (mg) U.S.P., J.P., Ph. Eur Inactive L-Methionine = 1 .4900 milligram (mg) U.S.P., J.P., Ph. Eur Inactive L-Arginine monohydrochloride = 14.7500 milligram (mg) U.S.P., J.P., Ph. Eur Inactive

	Trehalose dihydrate = 50.0000 milligram (mg) U.S.P. J.P., Ph. Eur Inactive Ziltivekimab =15.0000 milligram(mg) In House Specification Active
Indications:	cardiovascular outcomes in participants with established ASCVD, CKD and systemic inflammation

Annexure:

Details of clinical trial site:

Sr. No.	Names and address of clinical trial site	Ethics committee details	Name of investigator
1.	Department of Nephrology, QQDC Building Osmania general Hospital, 3rd Floor. Afzalgunj, Hyderabad 500012, Telangana, India	Institutional Ethics Committee, Osmania Medical College Koti, Hyderabad-500095, Telangana, India. ECR/300/Inst/AP/2013/RR-19	Dr. Manisha Sahay
2.	Department of Cardiology, King George's Medical University, Lucknow (Uttar Pradesh), India-226003	Institutional Ethics Committee, King George's Medical College Situated at Office of Research Cell, Administrative Block, King George's Medical University, Lucknow (Uttar Pradesh), India-226003 ECR/262/Inst/UP/2013/RR-19	Dr. Rishi Sethi
3.	Gurunanak CARE Hospital, 1-4-908/7/1, Bakararn, Musheerabad main Road, Musheerabad, Hyderabad-20	Institutional Ethics Committee, #6-3-24812, CARE Hospital, In patient Building 4'"Floor, Room No-401, Road No -01, Banjara Hills, Hyderabad -500034 ECR/94/Inst/AP/2013/RR-19	Dr. Johann Christopher
4.	Room No. 122, Department of Medicine, B L Taneja Block Maulana Azad Medical College, New Delhi-110002	Institutional Ethics Committee Room No. 306 B, 3 Floor, Maulana Azad Medical College, New Delhi-02 ECR/329/Inst/DL/2013/RR-19	Dr. Sunita Aggarwal
5.	Sunrise Hospitals (A Unit of NS Health Care Services Pvt. Ltd) #33-25-35, Near Pushpa Hotel Centre, Opp. Corporation Bank, Bellapu Sobhanadri Road, Vijayawada-520002, Andhra Pradesh, India	Institutional Ethics Committee Sunrise Hospitals, (A Unit of NS Health Care Services Pvt. Ltd) #33-25-35, Near Pushpa Hotel Centre, Opp. Corporation Bank, Vijayawada-520002, Andhra Pradesh, India ECR/756/Inst/AP/2015/RR-18	Dr. Krishna M.V.S
6.	Department of Nephrology, Super Speciality Block, Medical College Hospital, Kozhikode-673008, Kerala, India	Institutional Ethics Committee, Government Medical College, Kozhikode, 4th Floor, Golden Jubilee Annex Institute of Maternal and Child Health, Medical College, PO, Calicut-	Dr. Jayakumar Edathedathe Krishnan

		673008 ECR/395/Inst/KL/2013/RR-20	
7.	Government Medical College and Super Speciality Hospital, Tukdoji Square, Nagpur-440009, Maharashtra, India	Institutional Ethics Committee, GMC, Nagpur, Government Medical College and Hospital, Medical Square, Hanuman Nagar, Nagpur - 440003, Maharashtra, India ECR/43/Inst/MH/2013/RR-19	Dr. Sunil Nilkanthrao Washimkar
8.	Sir Ganga Ram Hospital, Old Rajinder Nagar, New Delhi-110060, India	Ethics Committee, Sir Ganga Ram Hospital, Old Rajinder Nagar, New Delhi-110060, India ECR/20/Inst/DL/2013/RR-16	Dr. Anil Kumar Bhalla
9.	Vijan Hospital & Research Centre (Vijan Cardiac & Critical Care (Centre), Dr. Vijan Hospital Marg College Road, Nashik-422005, Maharashtra, India	Vijan Hospital Ethics Committee Vijan Cardiac & Critical Care Centre, Dr. Vijan Hospital Marg, College Road, Nashik-422005, Maharashtra, India ECR/406/Inst/MH/RR-16	Dr. Vinodkumar M. Vijan
10.	Max Super Speciality Hospital,1-Press Enclave Road, Saket, New Delhi-110017	Max Healthcare Ethics Committee, Max Super Speciality Hospital,1-Press Enclave Road, Saket, New Delhi-110017 ECR/118/INST/DL/2013/RR-19	Dr. Dinesh Khullar
11.	KLES Dr. Prabhakar Kore Hospital and Medical Research Centre, Nehru Nagar, Belagavi-590010, Kamataka, India	Institutional Ethics Committee KLE University, KLES Dr P'K Hospital and MRC, Nehru Nagar, Belagavi (Belgaum)-590010, Kamataka, India. ECR/211/Inst/KA/2013/RR-19	Dr. Prasad. M. R
12.	Medanta Institute of Medical Sciences, Lucknow, Sector-A, Pocket-1, Shushant Golf City, Amar Shaheed Path, Lucknow-226030	Institutional Ethics Committee Medanta Lucknow (IECML), Room No. 1, Lower Ground Floor, Medanta Hospital, Sector-A, Pocket-1, Shushant Golf City, Amar Shaheed Path, Lucknow-226030 ECR/1529/Inst/UP/2021	Dr. Manish Gutch
13.	Omega Hospitals (P) Ltd., Mahaveer Circle Kankanady, Mangalore-575002,Karnataka, India	Omega Ethical Committee, Omega Hospitals (P) Ltd., Mahaveer Circle Kankanady, Mangalore-575002,Karnataka, India ECR/89/Inst/KA/2013/RR-20	Dr. Mukund Kumbla

14.	Kasturba Medical College and Hospital, Manipal Academy of Higher Education, Madhava Nagar, Manipal-576104, Karnataka, India	MAHE Ethics Committee, Mezzanine Floor, KMC Old Library Building, Manipal-576104 ECR/191/inst/KL/2013/RR-19	Dr. Tom Devasia
15.	Shree Mahavir Health and Medical Relief Society, Shri Bachubhai Dahyabhai Mehta Mahavir Heart Institute, Shree Mahavir Health Campus, Athwagate, Ring Road, Surat-395001, Gujarat, India	Shri B D Mehta Mahavir Heart Institute Ethics Committee, Shree Mahavir Health Campus, Athwagate, Opp, Vanita Vishram Ground, Athwagate, Ring Road, Surat-395001, Gujarat, India ECR/850/Inst/GJ/2016/RR-20	Dr. Atul Damodar Abhyankar
16.	VMMC & Safdarjung Hospital, New Delhi-110029	Institutional Ethics Committee, VMMC & amp; Safdarjung Hospital Room No. 505 & 506, 5th floor, Main OPD Building, VMMC & Safdarjung Hospital, New Delhi-110029 ECR/593/Inst/DL/2014/RR-20	Dr. Sandeep Bansal
17.	Unicare Heart Institute and Research Center, Acme Plaza, B-Wing, Near Sosyo Circle, B/H New Civil Hospital, Canal Road, Surat-395002, Gujarat, India	Unity Hospital Ethics Committee, Unity Trauma Center and ICU, N-4 Janki Park Society, Aai Mata Road, Paravat Patiya, Surat Gujarat-395010, India ECR/595/Inst/GJ/2014/RR-20	Dr. Devangkumar Maheshchandra Desai
18.	Shrikrishna Hrudayalaya and Critical Care Centre, Tikekar Road, Congress Nagar Square, Dhantoli, Nagpur-440012	Virtuous Institutional Medical Research Ethics Committee, IV th Floor, Shrikrishna Hrudayalaya and Critical Care Centre, Tikekar Road, Congress Nagar Square, Dhantoli, Nagpur-440012 ECR/548/Inst/MH/2014/RR-20	Dr. Mahesh Fulwani
19	K.E.M. Hospital & Seth G.S. Medical college, 4th Floor, CVTC Building, Department of Cardiology, Acharya Donde Marg, Parel 400012 Mumbai, Maharashtra, India	Institutional Ethics Committee New UG/PG Hostel, 20th storey Hostel Building, Ground floor, KEM Hospital campus, Near main boys hostel, Or S.S.Rao's Marg, Gate No. 07, Parel, Mumbai 400012, Maharashtra India ECR/229/Inst/MH/2013/RR-19	Dr. Prafulla Kerkar
20.	Batra Hospital ard Medical Research Centre, 1, Tughlakabad Institutional Area, Mehrauli-Badarpur Road, New Delhi-110062	Scientific Research and Ethical Review Committee, Department of Laboratory Medicine, Batra Hospital and Medical Research Centre,1, Tughlakabad Institutional Area,	Dr. Upendra Kaul

		Mehrauli-Badarpur Road, New Delhi-110062 ECR/295/Inst/DL/2013/RR-19	